BUSINESS● LOW2h ago · Oct 19, 2026, 5:25 PM
AnaptysBio gains as GSK granted FDA label expansion for Jemperli
Seeking Alpha Tech · north america
AnaptysBio has seen gains following GSK receiving an FDA label expansion for its drug Jemperli. This indicates a positive development for GSK and a correlated market reaction for AnaptysBio, likely due to partnerships or shared interests.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS18m agoAnthropic nearing second $45B deal with Nscale for compute power: reportSeeking Alpha TechBUSINESS23m agoLiveRamp gains after FTC approves $2.5B sale to Publicis with conditionsSeeking Alpha Tech